indinavir-sulfate and Hepatitis--Viral--Human

indinavir-sulfate has been researched along with Hepatitis--Viral--Human* in 2 studies

Other Studies

2 other study(ies) available for indinavir-sulfate and Hepatitis--Viral--Human

Article	Year
Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Jul-15, Volume: 39, Issue:2 Risk factors associated with the occurrence of protease inhibitor (PI)-related severe and serious adverse drug reactions (SADRs) were analyzed in a prospective cohort of 1155 patients who initiated PI-containing therapy. During a total follow-up of 2037 patient-years, 169 SADRs were reported, yielding a rate of 8 incidents per 100 patient-years (95% confidence interval [CI], 6.8-8.6). The most frequent SADRs were elevated transaminase levels (in 49 events); renal colic (27); abnormal hematological findings (23); and metabolic (18), neuromuscular (7), pancreatic (6), cutaneous (6), cardiovascular (5), and psychiatric disorders (5). Among baseline characteristics, plasma human immunodeficiency virus RNA levels of >or=5 log(10) copies/mL (hazard ratio [HR], 1.5; 95% CI, 1.1-2.2), elevated aspartate aminotransferase levels (HR, 1.1 for each 20 IU of elevation; 95% CI, 1.1-1.2), creatinine clearance levels of <70 mL/min (HR, 2.1; 95% CI, 1.2-3.7), test results positive for hepatitis C virus antibodies or hepatitis B surface antigenemia (HR, 2.6; 95% CI, 1.8-3.7), and receipt of indinavir (HR, 1.7; 95% CI, 1.2-2.4) were independently predictive of a SADR. SADRs were frequent in the first 4 months after initiation of highly active antiretroviral therapy but continued to occur after that time period. Topics: Adult; Colic; Female; Hepatitis, Viral, Human; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Indinavir; Kidney Diseases; Male; Probability; Prospective Studies; Renal Insufficiency; Risk Factors; Time Factors; Transaminases	2004
Clearance of hepatitis G viremia in a human immunodeficiency virus-positive patient by high-activity antiretroviral therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1999, Volume: 29, Issue:5 Topics: Adult; Flaviviridae; Hepatitis, Viral, Human; HIV Protease Inhibitors; HIV Seropositivity; Humans; Indinavir; RNA, Viral; Viremia	1999

Article

Year

Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Jul-15, Volume: 39, Issue:2

Risk factors associated with the occurrence of protease inhibitor (PI)-related severe and serious adverse drug reactions (SADRs) were analyzed in a prospective cohort of 1155 patients who initiated PI-containing therapy. During a total follow-up of 2037 patient-years, 169 SADRs were reported, yielding a rate of 8 incidents per 100 patient-years (95% confidence interval [CI], 6.8-8.6). The most frequent SADRs were elevated transaminase levels (in 49 events); renal colic (27); abnormal hematological findings (23); and metabolic (18), neuromuscular (7), pancreatic (6), cutaneous (6), cardiovascular (5), and psychiatric disorders (5). Among baseline characteristics, plasma human immunodeficiency virus RNA levels of >or=5 log(10) copies/mL (hazard ratio [HR], 1.5; 95% CI, 1.1-2.2), elevated aspartate aminotransferase levels (HR, 1.1 for each 20 IU of elevation; 95% CI, 1.1-1.2), creatinine clearance levels of <70 mL/min (HR, 2.1; 95% CI, 1.2-3.7), test results positive for hepatitis C virus antibodies or hepatitis B surface antigenemia (HR, 2.6; 95% CI, 1.8-3.7), and receipt of indinavir (HR, 1.7; 95% CI, 1.2-2.4) were independently predictive of a SADR. SADRs were frequent in the first 4 months after initiation of highly active antiretroviral therapy but continued to occur after that time period.

Topics: Adult; Colic; Female; Hepatitis, Viral, Human; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Indinavir; Kidney Diseases; Male; Probability; Prospective Studies; Renal Insufficiency; Risk Factors; Time Factors; Transaminases

2004

Clearance of hepatitis G viremia in a human immunodeficiency virus-positive patient by high-activity antiretroviral therapy.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1999, Volume: 29, Issue:5

Topics: Adult; Flaviviridae; Hepatitis, Viral, Human; HIV Protease Inhibitors; HIV Seropositivity; Humans; Indinavir; RNA, Viral; Viremia

1999